Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05708976 · ClinicalTrials.gov registry record · NA
HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT05708976: Completed NA study, sponsored by University of California, San Francisco.
NCT05708976 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05708976, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This randomized two-arm intervention trial administers 8 weekly cognitive behavioral therapy (CBT) sessions and 4 bi-weekly active whole-body hyperthermia (active WBH) sessions or 4 bi-weekly sham WBH sessions to adults aged 18 years or older with major depressive disorder (MDD).
Primary Outcome
Study acceptability was indexed by participant-reported net-promoter scores. This is a response to a single question: "How likely would you be to recommend \[participation in a study or treatment like this\] to a friend or family member with depression?" Net promoter scores range from 0 (would not recommend) to 10 (would definitely recommend). Study acceptability was also indexed by an additional patient-reported metric, Enrollment Likelihood. Enrollment likelihood was a response to the question
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy (CBT)
- DEVICE Active Whole-Body Hyperthermia (Active WBH)
- DEVICE Sham Whole-Body Hyperthermia (Sham WBH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2024-09-30 |
| Phase | NA |
What the finished NCT05708976 record still lists
NCT05708976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Cognitive Behavioral Therapy (CBT) is the first listed.
NCT05708976 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05708976 about?
NCT05708976 is a clinical study titled "HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2". This randomized two-arm intervention trial administers 8 weekly cognitive behavioral therapy (CBT) sessions and 4 bi-weekly active whole-body hyperthermia (active WBH) sessions or 4 bi-weekly sham WBH sessions to adults aged 18 years or older with major depressive disorder (MDD).
What is the current status of trial NCT05708976?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2023-02-15. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT05708976?
The interventions under investigation include: Cognitive Behavioral Therapy (CBT) (BEHAVIORAL), Active Whole-Body Hyperthermia (Active WBH) (DEVICE), Sham Whole-Body Hyperthermia (Sham WBH) (DEVICE).
Who is sponsoring clinical trial NCT05708976?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05708976's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI